ICIrene Llorente Cubas

Irene Llorente Cubas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Irene Llorente Cubas has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    POS0917 EFFECTIVENESS AND SAFETY OF COMBINED BIOLOGICAL THERAPY IN PATIENTS WITH REFRACTORY SPONDYLOARTHRITIS

    by C. Valero, J. P. Baldivieso, I. Llorente, E. Tomero Muriel, I. González-Álvaro, S. Castañeda, R. Garcia de Vicuna

    Background: Biological therapy in combination is discouraged in the guidelines for the treatment of immune-mediated inflammatory diseases, attending to safety reasons. However, combined biological therapy could be a valid alternative in patients with highly refractory spondyloarthritis (SpA) as has been previously demonstrated in some reluctant inflammatory bowel disease patients. Published experiences in the literature are very scarce and the follow-up is limited. Objectives: The aim of this study is to determine the effectiveness and safety of the association of biological drugs in patients with SpA and describe the clinical profile of these patients. Methods: This is a retrospective, cross-sectional and descriptive study. We included patients with SpA who had received simultaneously at least two biological drugs with different therapeutic targets. We reviewed the database of our hospital that included all patients diagnosed with SpA meeting the ASAS criteria for axial SpA under active biological treatment. Demographics, clinical and laboratory data, previous treatments, disease activity index (ASDAS CRP) and adverse events were collected. Remission and low activity criteria were considered according to cut-off descriptions in ASDAS CRP, Results: We identified six patients with SpA receiving combined biological therapy (Table 1). All patients showed high disease activity at the start of combination treatment and most of them presented several disease domains involvement. The average of previous biologics drugs was 5.33 ± 1.75. Four patients received an anti-TNF in combination with an anti-IL17 agent and one patient with concomitant Crohn disease was prescribed an anti-TNF combined with an anti-IL23 agent. The sixth patient, with SpA and concomitant systemic lupus erythematosus, received rituximab with an anti-IL17 (Table 1). The median treatment duration of the combined biological therapy was 12.5 months (IQR 4-43.5; range: 4-117). All patients achieved low disease activity or clinical remission at some point during follow-up, allowing for initial de-escalation of initial dose in some patients. Only one patient experienced a transient relapse (unic uveitis episode). No relevant adverse effects have been found clearly attributable to combination therapy. A 60-year-old patient with multiple comorbidities has stopped treatment due to aggravation of a previous liver cirrhosis. Conclusion: Combined biological therapy could be an effective therapeutic alternative to patients with multidomain and refractory SpA. In our series, we provide acceptable safety data for follow-up periods that it are longer than the majority of reported cases to date. Main characteristics of patients with SpA and treatment schedules. Disclosure of Interests: None declared


  • Open Access

    POS0627 SHORT-TERM EFFECT OF ANTI-IL-6 THERAPY ON ADIPONECTIN SERUM LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS

    by S. Remuzgo-Martínez, V. Pulito-Cueto, F. Genre, J. Calvo, E. Aurrecoechea, I. Llorente, A. Triguero-Martinez, R. Blanco, J. Llorca, M. E. Ruiz, et al.

    Background: Adiponectin is an adipokine with anti-inflammatory, anti-atherosclerotic and cardioprotective effects that also contributes to the pathogenesis of metabolic syndrome (MetS) [1]. MetS is frequently observed in patients with rheumatoid arthritis (RA), increasing the risk of cardiovascular (CV) morbidity and mortality in these patients [1-3]. A recent study of our group disclosed a short-term effect of anti-IL-6 therapy on serum levels of leptin (another adipokine with pro-inflammatory functions, related with MetS and CV disease) in RA patients [4]. Accordingly, it is plausible to think that such treatment may also have an effect in adiponectin levels. Objectives: To determine the short-term effect of the anti-IL-6 receptor tocilizumab (TCZ) administration on circulating adiponectin serum levels in patients with RA, as well as the potential association of adiponectin with demographic and clinical features of these patients. Methods: 50 consecutive Spanish patients undergoing periodic treatment with TCZ who fulfilled the 2010 classification criteria for RA [5] were recruited. Adiponectin serum levels were assessed in samples obtained immediately prior to (pre-infusion) and 60 minutes after the end of a TCZ intravenous infusion (post-infusion) by a commercial Enzyme-Linked ImmunoSorbent Assay (ELISA) kit. Results: Similar serum levels of adiponectin were found following the TCZ infusion (mean ± standard deviation: 23.01 ± 18.58 µg/mL versus 22.35 ± 17.84 µg/mL, pre- and post-infusion, respectively, p=0.69). Additionally, there was a negative correlation between adiponectin basal levels and body mass index (r=-0.45, pConclusion: Our study suggests that anti-IL-6 therapy has no short-term effect on adiponectin serum levels in patients with RA. Furthermore, our results support that low adiponectin levels are associated with MetS features and, therefore, with CV disease in RA. References: [1]Biochem Pharmacol. 2019;165:196-206; [2] Clin Exp Rheumatol. 2008;26:596-603; [3] Mediators Inflamm. 2013;2013:710928; [4] Clin Exp Rheumatol 2020;38:1201-1205; [5] Arthritis Rheum. 2010;62:2569-2581. Acknowledgements: Personal funds: SR-M: RD16/0012/0009 (ISCIII-ERDF); VP-C: PREVAL 18/01 (IDIVAL); OG: GPC IN607B2019/10 (GAIN); RL-M: Miguel Servet type I programme CP16/00033 (ISCIII-ESF). Disclosure of Interests: Sara Remuzgo-Martínez: None declared, Verónica Pulito-Cueto: None declared, Fernanda Genre: None declared, Jaime Calvo: None declared, Elena Aurrecoechea: None declared, Irene Llorente: None declared, Ana Triguero-Martinez: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Javier Llorca: None declared, M E Ruiz: None declared, Natalia Rivera: None declared, Oreste Gualillo: None declared, Raquel López-Mejías: None declared, Santos Castañeda: None declared, Miguel A González-Gay Speakers bureau: Pfizer, Abbvie, MSD, Grant/research support from: Pfizer, Abbvie, MSD.


  • Factores asociados a la persistencia a largo plazo de rituximab en artritis reumatoide en la práctica clínica: Estudio RITAR

    by Iciar Cañamares Orbis, Leticia Merino Meléndez, Irene Llorente Cubas, Juana Benedí González, Rosario García-Vicuña, Alberto Morell Baladrón, Isidoro González-Álvaro, Esther Ramírez Herraiz


  • Open Access

    AB1339-HPR SAFETY AND ADHERENCE OF THE JAK INHIBITORS IN CLINICAL PRACTICE IN RHEUMATOID ARTHRITIS

    by C. Valero, A. Calvo Garcia, N. García Castañeda, A. Ortiz, I. Llorente, B. Varas, S. Castañeda, R. Garcia de Vicuna, E. Ramirez

    Background: The Janus Kinase (JAKi) inhibitors Baricitinib (BAR) and Tofacitinib (TOF) are indicated for moderate to severe active rheumatoid arthritis (RA). Data about safety, effectiveness in refractory patients and adherence in real clinical practice in our population are scarce. Objectives: An evaluation of safety, adherence and reasons to consider suspension of JAKi in routine clinical practice. Methods: Retrospective observational study of patients with RA treated with BAR and TOF according to usual clinical practice between September 2017 - December 2019. Data were collected from the electronic medical record and from the Dominion® Outpatient Drug Dispensing program. Demographic, clinical, laboratory and treatment-related variables were collected, including reasons for discontinuing JAKi (inefficiency and toxicity). Adherence was calculated using the Compliance Questionnaire on Rheumatology (CQR-5), and the average possession ratio (RMP), which is defined as the number of days with treatment dispensed between the total days of the period analyzed, considering the adherent patient when RMP had a ≥ 0.8. Laboratory abnormalities were defined according to normal limit values (NLV) and specifications of data sheet. A descriptive analysis was performed using proportions, medians and interquartile ranges (IQR) using the SPSS v.15 program. Results: Thirty patients were included in treatment with BAR and nine with TOF. The median age was 62.9 (RIQ 49.9-74.4), 34 (87.2%) were women, 28 (71.2%) anti-CCP and 32 (82.1%) were rheumatoid factor positive, with erosive disease in 34 (87,2%) patients. In the previous treatment, 9 (23.1%) were naive to biological, 6 (15.4%) had received 1 biological, 18 (46.1%) 2 biologicals, and 6 (15.4%) ≥ 3 biologicals. The median treatment time was 8.4 months (RIQ 6.5-20.3) in BAR and 13.2 (RIQ 3.9-20.7) in TOF. The reasons for consider suspension shown in Table 1. Treatment Discontinuation Safety results of the treatment shows the safety results. Conclusion: In our population, mostly refractory to biological, more than half of the patients maintain treatment with JAKi, with optimal adherence. The main reason for the suspension of both drugs was inefficiency. The most frequent adverse effects were hypercholesterolemia in both groups and infections in BAR, with a high frequency of herpes zoster. No cardiovascular or thromboembolic events were observed. Disclosure of Interests: Cristina Valero: None declared, Alberto Calvo Garcia: None declared, Noelia García Castañeda: None declared, Ana Ortiz: None declared, Irene Llorente Speakers bureau: Gebro, Janssen, Sanofi, Lilly., Blanca Varas: None declared, Santos Castañeda: None declared, Rosario Garcia de Vicuna Grant/research support from: BMS, Lilly, MSD, Novartis, Roche, Consultant of: Abbvie, Biogen, BMS, Celltrion, Gebro, Lilly, Mylan, Pfizer, Sandoz, Sanofi, Paid instructor for: Lilly, Speakers bureau: BMS, Lilly, Pfizer, Sandoz, Sanofi, Esther Ramirez: None declared


  • Open Access

    Cholinergic modulation of spontaneous hypothalamic-pituitary-adrenal activity and its circadian variation in man.

    by I Llorente, F Lizcano, R Alvarez, N Diez, M Sopena, M J Gil, J Salvador

    Controversy still exists regarding the role of cholinergic pathways in the regulation of the hypothalamic-pituitary-adrenal axis in man. We studied the effects of the administration of placebo, pyridostigmine (PD); 120 mg, orally), and the combination of PD and pirenzepine (PZP; 100 mg, orally) on ACTH, cortisol, and GH secretion at 0730 and 2230 h in seven normal males. PD induced a clear decrease in ACTH levels at both times of the day compared to treatment with placebo, producing higher suppression in the nocturnal period (34.4 +/- 5.8% vs. 21.8 +/- 10.7%). The combination PD and PZP prevented the inhibitory action of PD on ACTH secretion in the morning, but not in the evening, when ACTH values showed a decrease similar to that seen after giving PD alone (38.1 +/- 5.6% vs. 34.4 +/- 5.8%, respectively). Cortisol values declined only when the association PD plus PZP was given in the evening. GH levels had a significant increase after PD administration in the morning (4.1 +/- 1.2 ng/mL) and in the evening (10.2 +/- 1.6 ng/mL), confirming that cholinergic stimulation was taking place, whereas the addition of PZP to PD induced a significant attenuation of these responses. It is concluded that cholinergic pathways have a inhibitory role in ACTH secretion in man. M1 muscarinic receptors seem to be involved in the diurnal inhibition of PD, whereas our observations are consistent with the mediation of another type of cholinergic receptors as an explanation for the nocturnal effect of PD on ACTH secretion. PD did not alter the circadian variation in the hypothalamic-pituitary-adrenal axis, whereas the association of PD and PZP increased the differences between diurnal and nocturnal ACTH values, suggesting a modulatory effect of the cholinergic system on the circadian rhythm of ACTH secretion.